**Curriculum Vitae**

**Brad Haverkos, MD, MPH, MS**

**Current Position**

9/1/15-pres Assistant Professor within Division of Hematology at University of Colorado

T and NK-cell leukemia/lymphoma program lead

**Education/Academic Training**

08/13-06/15 Graduate School, *The Ohio State University*, Columbus, Ohio

Degree: Masters of Medical Science

07/13-06/15 Post-doctoral fellowship, Clinical T32 Research Fellow

05/14-06/14 External Visiting Fellow at NCI/CTEP, Washington DC

Responsible for reviewing incoming LOIs and protocols

07/12-06/14 Oncology Fellowship at The Ohio State University

07/09-06/12 Internal Medicine Residency, *University of Illinois,* Chicago, IL

08/05-05/09 Medical School, *Boonshoft School of Medicine at Wright State University,* Dayton, Ohio

Degree: Doctor of Medicine

08/05-05/09 Graduate School, *Wright State University*, Dayton, Ohio

Degree: Masters of Public Health

08/99-05/03 Undergraduate School, *Miami University,* Oxford, Ohio

Degree: Bachelor of Arts, Psychology; Neuroscience minor

**Selected Honors and Awards**

2014 Completion of the ASCO/AACR educational workshop “Methods in Clinical Cancer Research” to work on a protocol using rhuFLT3L (CDX-301) to mobilize stem cells for autologous stem cell transplantation

2013 Certificate of completion for 2013 Advanced Course in Immunology

2013 Certificate of completion for 2013 Introductory Course in Immunology-Parts I & II

2009 Outstanding Senior Medical Student in Internal Medicine

2009 Boonshoft Physician Leadership Development Scholarship, Wright State University

2009 Certificate for completion of the international health program at Wright State University

2002 Research Assistant & Summer Scholars Award, Miami University

2002 College of Arts and Science Scholarship, Miami University

**Professional Positions, Organizations and Committees**

Internal (University of Colorado):

* Co-lead the multi-disciplinary cutaneous lymphoma clinic with Dr. Theresa Pacheco
* Co-chair for the Lymphoma Committee Working Group – Responsible for publishing internal practice management guidelines
* Central Nervous System Lymphoma Working Group Member - Responsible for publishing internal practice management guidelines
* Scientific reviewer for COMIRB– Panel D
* Bone Marrow Transplant Disease Group Committee Member - Responsible for internal standard operating procedures including development of guidelines around haploidentical transplantation for lymphoma patients.
* Lead Academic Participating Site (LAPS) Steering Committee: Responsible for reviewing and deciding which clinical trials should be supported throughout the University of Colorado Health network of hospitals
* Global Health Program Liaison for the Division of Hematology

External:

6/2016-pres     Leukemia Lymphoma Society Board of Trustees – Rocky Mountain Chapter

1/2018-pres Cutaneous Lymphoma Foundation Research Advisory Council Member

2018 ASH News Daily Editorial Board

National/International Committee Memberships:

04/17-pres T-cell and primary cutaneous lymphoma NCCN guidelines panel member

02/14-pres CIBMTR working committees for lymphoma and PD-1 Blockade and Allo-Transplant

02/14-2016 CIBMTR working committee for autoimmune diseases and cellular therapy

Society Memberships:

2018-pres Member of the Human Immunology & Immunotherapy Initiative

2015-pres Associate Member of University of Colorado Cancer Center

2014-pres United States Cutaneous Lymphoma Consortium

2013-pres American Society for Blood and Marrow Transplantation

2012-pres American Society of Hematology

2012-pres American Society of Clinical Oncology

2014-2016 American Association for Cancer Research

2013-2016 American Association of Immunology

2005-2009 American College of Physicians

2004-2009 American Medical Association

**Board Certification and Medical Licensure**

08/12-pres American Board of Internal Medicine

2016-pres American Board of Internal Medicine-Medical Oncology

6/18/15-4/30/19 State of Colorado Medical License

6/2015-10/31/19 DEA License

Valid through 8/2019 Basic and Advanced Cardiac Life Support (BLS and ACLS)

**Journal Refereeing:**

Associate Editor for Frontiers in Oncology (Hematology-Oncology section; 2018-2019)

Guest Associate Editor for a Research Topic special issue on EBV-associated lymphomas in Frontiers in Oncology (2019)

**Ad-Hoc Reviewer for the following journals and topics**

BBMT, Immunotherapy, GVHD, PTLD (2019)

BMT, Immunotherapy (2018, 2019 x2)

Blood, NK/T-cell lymphoma (2018, 2019)

International Journal of Hematologic Oncology, Peripheral T-cell lymphoma

Cancer Immunology, Immunotherapy

JNCCN

Cancer Immunology, Immunotherapy

AJH

OncoTargets and Therapy

**Invited extramural lectures, presentations and visiting professorships**

Internal (University of Colorado):

New and emerging therapies in peripheral T-cell lymphomas. Hematology Grand Rounds. January 29, 2019.

Cutaneous Lymphomas – University of Colorado, Division of Hematology, Grand Rounds. October 24, 2017.

“Non-cutaneous” mature T and NK-cell Lymphoproliferative Disorders – University of Colorado, Division of Hematology, Grand Rounds. October 10, 2017.

Hematology Grand Rounds at University of Colorado. CNS Lymphomas: Past, Present, and Future. May 2, 2017.

Hematology Grand Rounds at University of Colorado. T-cell lymphoma. November 2016.

Hematology Grand Rounds at University of Colorado. CNS Lymphomas: Past, Present, and Future. November 3, 2015.

Local/Regional:

Lymphoma 101. Sponsored by Colorado Academy of Physician Assistants CME Conference 2019. Copper Mountain, CO. February 9, 2019.

Cutaneous lymphomas and aggressive B and T-cell lymphomas. Lymphoma Research Foundation Patient Education Seminar. Denver, CO. September 6, 2018.

Aggressive non-Hodgkin lymphomas. Grand Rounds. Good Samaritan Hospital. Lafayette, CO. September 6, 2018.

CTCL Diagnosis and Staging. Cutaneous Lymphoma Foundation Patient Educational Forum. October 28, 2018, Denver CO.

CTCL Treatments for Advanced Stage Disease. Cutaneous Lymphoma Foundation Patient Educational Forum. October 28, 2018, Denver CO.

Aggressive Lymphoma Review - For patients and caregivers. Leukemia Lymphoma Society Patient Education Conference. April 7, 2018.

Aggressive Lymphoma Review - For patients and caregivers. Leukemia Lymphoma Society Patient Education Conference. April 8, 2017.

Lymphoma Review – For healthcare professionals. Leukemia Lymphoma Society Patient Education Conference. April 8, 2017.

Ask the Doctor. Lymphoma Research Foundation. T and NK-Cell Lymphomas: Updates on Treatment. April 13, 2016.

ASH Review on T-cell lymphomas and bone marrow transplantation at University of Colorado. December 18, 2015.

National

T-cell Lymphomas. Lymphoma Research Foundation. 2019 Arizona Lymphoma Workshop. Scottsdale, AZ. February 2, 2019.

New and emerging therapies in peripheral T-cell lymphomas. Lymphoma Research Foundation Patient Education Forum. Lymphoma Research Foundation. Manhattan Beach, CA. October 14, 2018.

**Teaching Activities**

Peripheral T-cell lymphomas. Advanced Practice Provider Seminar. June 12, 2018.

Mature T-cell leukemias and lymphomas. Hem/Onc Fellow Education Conference. Jan 26, 2018.

Hemophagocytic Lymphohistiocytosis- For advanced practice providers. Jan 11, 2018.

Virus associated lymphomas. BIC breakfast talk. March 14, 2018.

Post Transplant Lymphoproliferative Disorders- For advanced practice providers. 2017.

Peripheral T-cell Lymphoma– For advanced practice providers. May 5, 2017.

Cutaneous T-cell Lymphoma – For advanced practice providers. May 5, 2017.

CNS Lymphoma – For advanced practice providers. April 28, 2017.

Aggressive Non-Hodgkin Lymphoma. Hem/Onc Fellow Education Conference. January 13, 2017.

Internal Medicine Residency Program Education Sessions “Primary CNS Lymphoma.” January 8, 2016.

Local Community Outreach and Education:

RMCC. Aurora, CO. April 6, 2016.

RMCC. 4715 Arapahoe Ave. Boulder, CO. August 3, 2016.

Memorial. 4010 North Briargate. Colorado Springs, CO. March 20, 2018.

RMCC. 2312 N. Nevada Ave. Colorado Springs, CO. March 20, 2018.

PVH. 2121 E. Harmony Rd. Ft. Collins, CO. March 22, 2018.

Mile High Family Medicine. 7444 W. Alaska Dr. Lakewood, CO. March 29, 2018.

National Jewish/Western Hematology Oncology. 400 Indiana St. Golden, CO. Drs. Jones and Kantor. May 29, 2018.

Ward and Clinic Attending Duties

2015 – present Supervision and bedside teaching of medical students, residents, fellows, nurse practitioners, and physicians’ assistants, 3 months/year inpatient (~15 inpatients/day), 1.5 days per week outpatient (~20 patients/week)

Mentorship

Alex Neuwelt – mentored during hem/onc fellowship (2018); currently faculty at VCU

**Grant support**

Active

CCTSI CO-Pilot Mentored Faculty Award $30,000 March 2019-April 2020

Leveraging immunotherapy to improve treatments for newly diagnosed peripheral T-cell lymphomas.

NIH Loan Repayment Program. Funding period 09/13- (L30 CA189070)

Evaluating the incidence and associated factors of detectable herpesvirus DNA in T & NKT cell lymphomas.

Completed Grant Funding

National Institute of Health training grant for the training of Hematology and Oncology Fellows in Clinical Research; PI: Villalona & Devine; 7/2013-6/2015; (NCI T32 CA165998)

NCI/NIH grant for the training of hematology and oncology fellows in clinical research.

Ongoing Clinical Trials

COMIRB #18-0708 Bristol Myers Squibb (PI: Haverkos) 9/2018-

Nivolumab with standard of care chemotherapy for the first line treatment of peripheral T-cell lymphoma

IRB #17-2074 Viracta Therapeutics (PI: Haverkos) 5/2018-

A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

IRB #18-1559 Rhizen Pharmaceuticals (PI: Haverkos) 10/2018-

An Open label, Compassionate Use Study of Tenalisib (RP6530) in Patients currently receiving treatment on Tenalisib trials in Hematological Malignancies

A Selected Sampling of Completed Clinical Trials

COMIRB #0759 University of Nebraska/Celgene (PI: Haverkos)

A Phase I/II Trial of CHOEP Chemotherapy plus Lenalidomide as Front Line Therapy for Patients with Stage II, III and IV Peripheral T‐Cell Non‐Hodgkin’s Lymphoma.

IRB #15-2381 Rhizen Pharmaceuticals (PI: Haverkos) .

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K δ/γ inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma

**Other Research and Support**

COMIRB #17-1038. Lymphoid Malignancies Tissue Bank.

Role: PI

COMIRB #16-2075. Laboratory-Based Investigations using Lymphoma Samples from the Hematology Tissue Bank.

Role: PI

COMIRB #18-0708 Bristol-Myers Squibb 9/2018-current

Nivolumab with standard of care chemotherapy for the first line treatment of peripheral T-cell lymphoma

Role: PI

**Bibliography**

Peer-Reviewed Papers

1) Haverkos, B., Oza, V., Johnson, A., Walker, J., & Shan’ah, A. Rare Presentation of Post-transplant Lymphoproliferative Disorder Isolated to Gastroesophageal Junction. World Journal of Gastrointestinal Oncology. 2013 Dec 15;5(12):230-4. PMID: 24363831. PMC3868718.

2) Haverkos, B. McBride, A., O’Donnell, L., Scholl, D. Whittaker, B., Vasu, S. Penza, S., Andritsos, L., Devine, S., & Jaglowski, S. An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. Bone Marrow Transplant. May 5, 2014. PMID: 24797182

3) Sborov, D., Haverkos, B., & Harris, P. A review of investigational cancer drugs targeting cell metabolism in clinical development. Expert Opinion on Investigational Drugs. 2014 Sep 16:1-16. PMID: 25224845 \*Co-author

4) Kaffenberger, B., Haverkos, B., Tyler, K., Porcu, P., Wong, H., & Gru, A. Extranodal Marginal Zone Lymphoma (MALT) - Like Presentations of Angioimmunoblastic T-cell lymphoma: A T-cell lymphoma masquerading as a B-cell lymphoproliferative disorder. American Journal of Dermatopathology. 2014.

5) Roddy, J., Haverkos, B., McBride, A., Leininger, K., Andritsos, L., & Devine, S. Tocilizumab in the Treatment of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. Leukemia & Lymphoma. 2015.

6) Haverkos, B., Tyler, K., Hu, Eileen, Philip, R., Gru, A., Welliver, M., Mishra, A., Wong, H., & Porcu, P. The role of an integrated multidisciplinary clinic in the management of patients with cutaneous lymphoma. Frontiers Oncol. 2015 Jun 17;5:136.

7) Haverkos, B., Tyler, K., Kartono, F., Frederickson, J., Elkins, C., Peters, S., Zhang, X., Wong, H., & Porcu, P. Presentation, management, and experience in treating primary cutaneous B-cell lymphoma in the Multimodality Cutaneous Lymphoma Clinic at the Ohio State University. Oncologist. 2015.

8) Haverkos BH, Gru AA, Freud AG, Hastings J, Nowacki NB, Barrionuevo C, Vigil CE, Rochford R, Natkunam Y, Baiocchi RA, et al. The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. Curr Hematol Malig Rep. 2015 Oct 8. \*Co-author

9) Yuan, S., Yu, J, Haverkos, B, & Su, H. Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. Leuk Lymphoma. 2016 Jan 6:1-3.

10) Haverkos, B., Gru, A., Geyer, S., Bingman, A., Hemminger, J., Mishra, A., Wong, H., Pancholi, P., Freud, A., Caligiuri, M., Baiocchi, R., Porcu, P., Elevated plasma levels of Epstein Barr Virus DNA identify a poor-risk subset of patients with advanced stage cutaneous T-cell lymphoma. Clinical Lymphoma, Myeloma, & Leukemia. August 2016.

11) Haverkos, B., Pan, Z., Gru, A., Freud, A., Rabinovitch, R., Xu-Welliver, M., Otto, B., Barrionueovo, C., Baiocchi, R., Rochford, R., & Porcu, P. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. Curr Hematol Malig Rep. October 2016.

12) Virmani, P., Hwang, S., Hastings, J., Haverkos, B., Kohnken, B., Gru, A., Mishra, A., Fabbro, S., Horwitz, S., & Porcu, P. Systemic therapy for cutaneous T-cell lymphoma: who, when, and why? Expert Rev Hematol. December 2016.

13) Haverkos, B. Huang, Y., Elder, P., O’Donnell, L., Scholl, D., Whittaker, B., Vasu, S., Penza, S., Andrtisos, L., Devine, S., & Jaglowski, S. A single center’s experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. BMT. January 2017.

14) Haverkos, B., Huang, Y., Gru, A., Pancholi, P., Freud, A., Mishra, A., Ruppert, A., Baiocchi, R., & Porcu, P. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. IJC. 2017 Apr 15;140(8):1899-1906.

15) Haverkos, B., Coleman, C., Gru, A., Pan, Z., Brammer, J., Rochford, R., Mishra, A., Oakes, C., Baiocchi, R., Freud, A., & Porcu, P. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). Discovery Medicine. 2017 Mar;23(126):189-199.

16) Haverkos, B, Abbott, D, Hamadani, M, Armand, P, Flowers, ME, Merryman, R, Kamdar, M, Kanate, AS, Saad, A, Mehta, A, Ganguly, S, Fenske, TS, Hari, P, Lowsky, R, Andritsos, L, Jagasia, M, Bashey, A, Brown, S, Bachanova, V, Stephens, D, Mineishi, S, Nakamura, R, Chen, YB, Blazar, BR, Gutman, J, & Devine, SM. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017.

17) Melani C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD, Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA, Pollyea DA, Smith CA, Wilson WH, Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. NEJM. 2017 Jul 6;377(1):89-91

18) Horwitz, S., Ansell, S., Ai, WZ, Barnes, J., Barta, S., Choi, M., Clemens, M., Dogan, A., Greer, J., Halwani, A., Haverkos, B., Hoppe, R., Jacobsen, E., Jagadeesh, D., Kim, Y., Lunning, M., Mehta, A., Mehta-Shah, N., Oki, Y., Olsen, E., Pro, B., Rajguru, S., Shanbhag, S., Shustov, A., Sokol, L., Torka, P., Wilcox, R., William, B., Zain, J., Dwyer, M., & Sundar, H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. JNCCN. 2018 Feb; 16(2): 123-135.

19) Haverkos, B., Dugan, J., Villagomez, L., Martin, L., Lustberg, M., Patton, J., Martin, M., Huang, Y., Nuovo, G., Yan, F., Cavaliere, R., Fingeroth, J., Kenney, S., Ambinder, R., Lozanski, G, Porcu, P., Caligiuri, M., & Baiocchi, R., Complete and durable responses in Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab and Dexamethasone. CCR. 2018. PMID: 29632007. \*Co-first author.

20) Shah, N., Woo Ahn, K., Litovich, C., Fenske, T., Ahmed, S., Battiwalla, M., Bejanyan, N., Bahi, P., Boalnos-Meade, J., Chen, A., Ciurea, S., Bachanova, V., DeFilipp, Z., Epperla, N., Farhadfar, N., Herrera, A., Haverkos, B., Holmberg, L., Hossain, N., Kharfan-Dabaja, M., Kenkre, V., Lazarus, H., Murthy, H., Nishihori, T., Rezvani, A., D’Souza, A., Savani, B., Ulrickson, M., Waller, E., Sureda, A., Smith, S., Hamadani, M. Outcomes of Medicare-age Eligible Patients with NHL Receiving Reduced-Intensity Allogeneic Transplantation. Blood Advances. 2018.

# 21) Sharma, P., Pollyea, D., Smith, C., Purev, E., Kamdar, M., Haverkos, B., Sherbenou, D., Rabinovitch, R., Hammes, A., & Gutman, J. Thiotepa Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared to Transplantation Following Standard Reduced-Intensity Conditioning: a Retrospective Cohort Comparison. BBMT. 2018.

22) Herbaux, C., Merryman, R., Devine, S., Armand, P., Houot, R., Morschhauser, F., & Haverkos, B. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018. PMID: 29720488

23) Coleman. C., Lang, J., Sweet, L., Smith, N., Freed, B., Pan, Z., Haverkos, B., Pelanda, R., & Rochford, R. Epstein-Barr virus type-2 infects T-cells and induces B-cell lymphomagenesis in humanized mice. JVI. August 2018.

24) Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J, Porcu P. Peripheral T-cell Lymphoma, not Otherwise Specified. (PTCL-NOS). Cancer Treat Res. 2019.

25) Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage desite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. Jan 2019.

26) Dugan, J., Coleman, C., Haverkos, B. Opportunities to target the life cycle of Epstein-Barr Virus (EBV) in EBV-associated lymphoproliferative disorders. Front Oncol. 2019

Book Chapters

1) Palmisiano, N., Haverkos, B., Gaballa, S., Filicko-O’Hara, J., Porcu, P., Kasner, M. Chapter 44 “Clinical Trials in Hematologic Malignancies.” From *Oncology Clinical Trials.* 2nd edition. 2018.

2) Rochford, R., Coleman, C., & Haverkos, B. Viral Infections and Hematologic Malignancies. Microbiome and Cancer. 2019.

Other products of scholarship

Authored the T-cell lymphoma regimens for www.chemopro.com

NCCN Chemotherapy Order Template Reviewer for primary cutaneous B-cell lymphoma regimens

Scientific Abstracts: Oral Presentations

Oki, Y., Zain, J., Haverkos, B., Barde, P., Penmetsa, K., & Huen, A. RP6530, a dual PI3K δ/γ inhibitor: Interim results of a Phase I/Ib Study in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma. T-cell Forum 2018.

Haverkos, B., Schowinsky, J., Kaplan, J., Kamdar, M., Kanate, A., Saad, A., Ganguly, S., Flowers, M., Fenske, T., Hari, P., Hamadani, M., Lowsky, R., Andritsos, L., Jagasia, M., Brown, S., Armand, P., Merryman, R., Bachanova, V., Stephens, D., Gutman, J., & Devine, S. Checkpoint Blockade For Treatment Of Lymphoma Following Allogeneic Stem Cell Transplant: Use May Be Complicated By Onset Of Severe Acute Graft Versus Host Disease. ASH, December 2016.

Haverkos, B., Huang, Y., Gru, A., Baiocchi, R., & Porcu, P. Elevated plasma Epstein-Barr virus DNA at diagnosis is a prognostic biomarker in peripheral T-cell lymphomas (PTCL). Presented at the 3rd Annual Summit on Practical and Emerging Trends in Lymphoid Malignancies & Multiple Myeloma; Whistler, BC. March 2016.

Haverkos, B., Huang, Y., Gru, A., Baiocchi, R., & Porcu, P. Elevated plasma Epstein-Barr virus DNA predicts a poor prognosis in peripheral T-cell lymphomas. Presented at the Society of Hematology Oncology; Houston, TX. September 2015.

Haverkos, B., Huang, Y., Gru, A., Baiocchi, R., & Porcu, P. Elevated plasma Epstein-Barr virus DNA predicts a poor prognosis in peripheral T-cell lymphomas. Presented at the 2nd Annual Summit on Practical and Emerging Trends in Lymphoid Malignancies & Multiple Myeloma; Whistler, BC. March 2015.

**A Selected Sampling of Abstract/Poster Presentations**

Porcu, P. Haverkos, B. et al. A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas. ASCO 2019.

Iver, S., Huen, A., Ferreri, A., Haverkos, B., Zain, J., Ramchandren, R., Lechowicz, M., Devata, S., Korman, N., Pinter-Brown, L., Delarue, R., Routhu, K., Barde, P., Nair, A., & Carlo-Stella, C. Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3K g/d Inhibitor in Patients with Relapsed/Refractory Lymphoid Malignancies. ASH 2018.

Mistry, N., Smith, D., Kamdar, M., Haverkos, B., & Ney, D. Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma. ASH 2018.

Sharma, P., Purev, E., Haverkos, B., Pollyea, D., Smith, C., Kamdar, M., Sherbenou, D., Mark, T. Forsberg, P., & Gutman, J. Chronic Graft Versus Host Disease Burden and Relapse Rates Are Lower with Comparable Overall Survival and Graft Versus Host Disease Free, Relapse Free Survival Following Adult Umbilical Cord Blood Compared to Matched Sibling Peripheral Blood Stem Cell Transplantation. ASH 2018.

Sharma, P., MacDonald, J., Kaiser, J., Tobin, J., Miller, M., Abidi, M., Benamu, E., Purev, E., Haverkos, B., & Gutman, J. Post Transplant Prophylaxis with High Dose Valacyclovir through Day 100 Versus Day of Post Transplant Hospital Discharge Decreases Cytomegalovirus Reactivation in Adult Umbilical Cord Blood Transplant Recipients. ASH 2018.

Oki, Y., Zain, J., Haverkos, B., Barde, P., Penmetsa, K., & Huen, A. RP6530, a dual PI3K δ/γ inhibitor: Interim results of a Phase I/Ib Study in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma. T-cell Forum 2018.

Oki, Y., Zain, J., Haverkos, B., Barde, P., Penmetsa, K., & Huen, A. Results of Ongoing Phase 1/1b study of RP6530, a dual PI3K δ/γ inhibitor in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. T-cell Forum 2018.

Lunning, M., Horwitz, S., Mehta-Shah, N., Advani, R., Beaven, A., Haverkos, B., Lechowicz, M., Oki, Y., Zain, J., Ansell, S. A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients with Stage II, III, and IV Peripheral T-cell Lymphoma: Phase 1 Results. Lugano 2017. T-cell Forum 2018. ASH 2018.

Oki, Y., Zain, J., Haverkos, B., Barde, P., Penmetsa, K., & Huen, A. Safety and Anti-Tumour Activity of RP6530, Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study. Lugano 2017. ASH 2017. ASCO 2018.

Querfeld, C., Foss, F., Porcu, P., Kim, Y., Pacheco, T., Haverkos, B., Halwani, A., DeSimone, J., William, B., Seto, A., Ruckman, J., Landry, M., Jackson, A., Pestano, L., Dickinson, B., Sanseverino, M., Rodman, D., Rubin, P., Gordon, G., & Phase 1 Trial Evaluating MRG-106, an Inhibitor of microRNA-155, Administered By Intratumoral, Subcutaneous, or Intravenous Delivery in Patients with Cutaneous T-cell Lymphoma (CTCL). Lugano 2017. ASH 2017. T-cell Forum 2018. ASCO 2018. ASH 2018.

Haverkos, B., Schowinsky, J., Kamdar, M. Andritsos, L., Gutman, J., & Devine, S. Severe acute graft versus host disease may complicate use of checkpoint blockade after allogeneic stem cell transplant in patients with classical Hodgkin lymphoma. Presented at ASH Lymphoma Biology; Colorado Springs, CO. June 2016.

Haverkos, B., Huang, Y., Gru, A., Baiocchi, R., & Porcu, P. Elevated plasma Epstein-Barr virus DNA predicts a poor prognosis in peripheral T-cell lymphomas. Presented at the Society of Hematology Oncology; Houston, TX. September 2015.

Haverkos, B., Huang, Y., Gru, A., Baiocchi, R., & Porcu, P. Elevated plasma Epstein-Barr virus DNA predicts a poor prognosis in peripheral T-cell lymphomas. Presented at the 2nd Annual Summit on Practical and Emerging Trends in Lymphoid Malignancies & Multiple Myeloma, March 2015.

Haverkos, B., Cortright, K. Andritsos, L., Blum, W., Klisovic, R., Vasu, S., Devine, S., & Jaglowski, S. A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies. Presented at ASH, December 2014.

Dugan, J., Haverkos, B., Martin, K., Martin, M., Patton, J., Lustberg, M., Nuovo, G., Yan, F., Cavaliere, R. Kenney, S., Fingeroth, J., Lozanski, G., Ramos, J., Porcu, P., Caligiuri, M., & Baiocchi, R. Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder. Presented at ASH, December 2014.

Haverkos, B., Hemminger, J., Geyer, S., Bingman, A., Wong, H., Gru, A., Ambinder, R., Baiocchi, R., & Porcu, P. Prognostic implications, predictive value, and latency analysis of Epstein-Barr virus (EBV) DNA in advanced stage cutaneous T-cell lymphoma (AS-CTCL). Published online May 2014. *Journal of Clinical Oncology (Meeting Abstracts),* 2014.

Haverkos, B., Geyer, S., McBride, A., Penza, S., Devine, S., Andritsos, L., & Jaglowski, S. Mobilization for Autologous Stem Cell Transplantation in Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma: A single institution experience. Presented at the February 2014 BMT Tandem Meeting.

Haverkos, B., Hemminger, J., Geyer, S., Bingman, A., Wong, H., Gru, A., Ambinder, R., Baiocchi, R., & Porcu, Prognostic value and latency analysis of serum Epstein-Barr Virus (EBV) DNA in advanced stage cutaneous T-cell lymphoma (CTCL). Presented at the January 2014 T cell forum.

Roddy, J., Haverkos, B., McBride, A., Leininger, K., Andritsos, L., & Devine, S. Tocilizumab in the Treatment of Steroid Refractory Graft Versus Host Disease: A Single Institutional Experience. Abstract #2067. Accepted ASH December 2013 annual meeting and exposition in New Orleans, LA. Also published online in the November 15 supplemental volume of Blood.

Haverkos, B., Hu, X., & Freeman, V. Oncologic Services and Cancer Mortality in Chicago: An Analysis from 1995 to 2004. Presented at Minority Health in the Midwest conference on February 24, 2012 in Chicago, IL.

Haverkos, B. Benefit Design of Medicare Drug Plans: An analysis of Ohio and the national landscape from 2006 through 2009. Presented at ACP conference October 2010 in Chicago, IL.

Griffin, A., Vesco, R. Haverkos, B. & Berry S. The effect of theta-triggered trial presentation on learning-related hippocampal activity in rabbits (oryctolagus cuniculus). Department of Psychology and Center for Neuroscience, Miami University. Presented at Society of Neuroscience conference November 2002 in Orlando, FL.